Lundbeck Head of R&D denies allergy aspirations

Lundbeck's recently initiated recruitment of grass allergy sufferers for a phase I trial does not herald changing winds at the pharmaceutical firm – no allergy market conquest is in the cards, says Head of R&D at Lundbeck Johan Luthman.

Lundbeck's headquarters in Denmark | Photo: Lundbeck / PR

It created ripples when it was recently uncovered that pharmaceutical firm Lundbeck is on the lookout for 36 grass allergy sufferers for a phase I study.

To some it might look as if the Danish company, which has traditionally worked within diseases like schizophrenia, depression and Alzheimer's, suddenly had ambitions of entering the allergy market, which is spearheaded by the Danish champion ALK.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs